FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer

Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the…

View More FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer

Farxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial

AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin). The data were presented as a late-breaking abstract (#19485)…

View More Farxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial
Chat with us
Loading...